BPC-157 + TB-500 Stack vs GHK (Glycine-Histidine-Lysine Tripeptide)
A neutral, side-by-side comparison of two healing & recovery peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
BPC-157 + TB-500 Stack
The most widely researched peptide stack for tissue repair, combining BPC-157 (angiogenesis and growth factor upregulation) with TB-500 (actin regulation and cell migration). The two compounds address complementary and non-overlapping stages of the healing cascade, producing synergistic effects in tendon, ligament, muscle, and gut injury research models.
Full profileGHK (Glycine-Histidine-Lysine Tripeptide)
The free tripeptide component of GHK-Cu before copper complexation. GHK naturally occurs in human plasma, saliva, and urine and promotes wound healing, collagen synthesis, and anti-inflammatory activity. While it readily chelates copper to form GHK-Cu in vivo, research distinguishes the independent effects of free GHK from the copper-complexed form on gene expression and tissue remodeling.
Full profile| BPC-157 + TB-500 Stack | GHK (Glycine-Histidine-Lysine Tripeptide) | |
|---|---|---|
| Category | Healing & Recovery | Healing & Recovery |
| Also known as | Wolverine Stack, BPC TB500 combination, healing stack, BPC-157 TB-500 | GHK tripeptide, Gly-His-Lys, copper chelating tripeptide, GHK free tripeptide |
| Evidence | Research-stage | Research-stage |
| Dosing range | BPC-157 250mcg + TB-500 2.5mg–BPC-157 750mcg + TB-500 7.5mg varies by component, 2–3x per week | 0.5mg–2mg mg, Daily or every other day (topical or SC) |
| Administration | Subcutaneous injection, Intramuscular injection | Subcutaneous injection, Topical (cream/serum) |
| Key side effects | BPC-157: nausea (rare), dizziness, lightheadedness, TB-500: fatigue, headache, injection site reactions, No documented combination-specific adverse effects, Theoretical oncological considerations (angiogenesis stimulation) — relevant in cancer history | Minimal reported side effects, Mild injection site irritation, Rare topical sensitization, No significant systemic effects at research doses |
| Cited sources | 2 references | 2 references |
Key differences
- Administration: BPC-157 + TB-500 Stack — Subcutaneous injection, Intramuscular injection; GHK (Glycine-Histidine-Lysine Tripeptide) — Subcutaneous injection, Topical (cream/serum).
- Dosing units differ: BPC-157 + TB-500 Stack is dosed in varies by component, GHK (Glycine-Histidine-Lysine Tripeptide) in mg — they operate at different scales.
- Frequency: BPC-157 + TB-500 Stack is typically 2–3x per week; GHK (Glycine-Histidine-Lysine Tripeptide) is Daily or every other day (topical or SC).
How each works
BPC-157 + TB-500 Stack
BPC-157 and TB-500 work through entirely non-overlapping mechanisms and have been combined in numerous community protocols for injury recovery. BPC-157 drives angiogenesis and growth factor receptor expression; TB-500 regulates actin polymerization and cell migration into the injury site. No documented negative interactions exist — the combination is considered synergistic in the healing research community based on the complementary biology of each compound.
GHK (Glycine-Histidine-Lysine Tripeptide)
Free GHK directly upregulates collagen, elastin, and laminin synthesis in fibroblasts through TGF-β pathway activation and metalloproteinase modulation. Loren Pickart's decades of research identified GHK as a potent tissue remodeling signal whose plasma concentrations decline with age. At physiologic concentrations, GHK resets approximately 31% of dysregulated gene expression associated with aging back toward a younger phenotype.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.